Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 2 countries.
Julio López-AbánInfectious and Tropical Diseases Group (e-INTRO), IBSAL-CIETUS (Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca), Faculty of Pharmacy, University of Salamanca, Ldo Méndez Nieto s/n, 37007 Salamanca, Spain.
Belén VicenteInfectious and Tropical Diseases Group (e-INTRO), IBSAL-CIETUS (Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca), Faculty of Pharmacy, University of Salamanca, Ldo Méndez Nieto s/n, 37007 Salamanca, Spain.
Elías Kabbas-PiñangoInfectious and Tropical Diseases Group (e-INTRO), IBSAL-CIETUS (Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca), Faculty of Pharmacy, University of Salamanca, Ldo Méndez Nieto s/n, 37007 Salamanca, Spain.ORCID 0000-0002-6290-9493
Juan Hernández-GoenagaInfectious and Tropical Diseases Group (e-INTRO), IBSAL-CIETUS (Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca), Faculty of Pharmacy, University of Salamanca, Ldo Méndez Nieto s/n, 37007 Salamanca, Spain.
Javier Sánchez-MontejoInfectious and Tropical Diseases Group (e-INTRO), IBSAL-CIETUS (Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca), Faculty of Pharmacy, University of Salamanca, Ldo Méndez Nieto s/n, 37007 Salamanca, Spain.ORCID 0000-0002-4227-9834
María AguirianoInfectious and Tropical Diseases Group (e-INTRO), IBSAL-CIETUS (Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca), Faculty of Pharmacy, University of Salamanca, Ldo Méndez Nieto s/n, 37007 Salamanca, Spain.
Esther Del OlmoDepartment of Pharmaceutical Chemistry, IBSAL-CIETUS, Faculty of Pharmacy, University of Salamanca, Ldo Méndez Nieto s/n, 37007 Salamanca, Spain.
Magnolia VanegasMolecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Carrera 50#26-20, Bogotá DC 111321, Colombia.
Manuel Alfonso PatarroyoMolecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Carrera 50#26-20, Bogotá DC 111321, Colombia.ORCID 0000-0002-4751-2500
Antonio MuroInfectious and Tropical Diseases Group (e-INTRO), IBSAL-CIETUS (Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca), Faculty of Pharmacy, University of Salamanca, Ldo Méndez Nieto s/n, 37007 Salamanca, Spain.ORCID 0000-0003-0244-4740
Universidad de Salamanca · ESFundación Instituto de Inmunología de Colombia · COUniversidad Nacional de Colombia · CO
Funding
Consejería de Educación, Junta de Castilla y León FEDER (Una manera de hacer Europa, Sistema Nacional de Garantía Juvenil, Cofinanciación por FEDER, and Iniciativa de Empleo Juvenil BDNS: 427002Instituto de Salud Carlos III RICET RD16/0027/0018 and PI19/01727Ministerio de Ciencia, Innovación y Universidades RTI2018-099474-B-I00
6 · The paper itself
Abstract
Schistosomiasis is a parasitic disease that affects 143 million people in endemic countries. This work analyzed overexpressed sequences from the cercaria phase to the early schistosomulum phase using bioinformatics tools to predict host interaction and selected proteins for predicting T cell epitopes. The final peptides were chemically synthesized, and their toxicity was evaluated in vitro. Peptides were formulated in the Adjuvant Adaptation (ADAD) vaccination system and injected into BALB/c mice that were challenged with
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
T Cell Peptides Derived from Invasive Stages of · full record | Socratic